Venrock

Venrock is a venture capital firm that was established in 1969 as the investment arm of the Rockefeller family. The firm focuses primarily on technology and healthcare sectors, partnering with entrepreneurs to build successful and lasting companies. Over the years, Venrock has invested in a diverse range of notable portfolio companies, which include industry leaders in various fields. Its commitment to fostering innovation and supporting talented founders has positioned Venrock as a key player in the venture capital landscape.

Ascher, Brian D.

Partner

Nick Beim

Partner

Bracken, Racquel N.

Partner

Steven Goldby

Partner

Todd Graham

Vice President

Ken Greenberg

Investor

Manjinder Kandola

Investor

Mariana Mihalusova

Vice President

David Pakman

Partner

Camille Samuels

Partner

Ganesh Srinivasan

Partner

Tyrrell, Michael F.

General Partner

Andy Wardle

Investor

826 past transactions

Astronomer

Series D in 2025
Astronomer, Inc. is a company based in Cincinnati, Ohio, that specializes in developing a managed Apache Airflow platform for data engineering. Founded in 2014, Astronomer offers Astro, a modern data orchestration platform that helps data teams enhance the availability of trusted data. This platform empowers users to build, run, and monitor data pipelines-as-code, making it easier for data engineers, scientists, and analysts to manage their workflows. By providing a suite of products and services that facilitate the deployment, management, and scaling of data pipelines, Astronomer aims to streamline the process of data collection and preparation for business analytics. The company's solutions are designed to support isolated resource allocation, user access, and account management, positioning it as a key player in the data orchestration landscape.

Expedition Therapeutics

Seed Round in 2025
Expedition Therapeutics operates as an unincorporated association.

Auditoria.AI

Series B in 2025
Auditoria.AI, Inc., founded in 2019 and based in Santa Clara, California, specializes in providing technology-driven financial solutions for enterprise accounting and auditing. The company leverages advanced artificial intelligence and machine learning to enhance compliance and streamline finance operations. Its flagship product utilizes natural language processing and predictive analytics to automate back-office processes, minimizing friction and repetition for finance teams. By focusing on automation, Auditoria.AI aims to deliver real-time insights that empower organizations to improve efficiency and decision-making in their financial operations.

Exceeds

Seed Round in 2025
Enterprise service combining AI and data insights to increase a team's impact

GenLogs

Series A in 2025
GenLogs is a freight intelligence company that offers truck carrier mapping services via AI-driven roadside sensors.

Oumi

Seed Round in 2025
Oumi is a group of academics, developers dedicated to fostering greater transparency and cooperation in frontier AI.

Suki

Series D in 2024
Suki is a technology company focused on enhancing healthcare documentation through AI-driven voice solutions. Its flagship product, Suki Assistant, allows physicians to complete administrative tasks more efficiently, significantly reducing the time spent on documentation. The company also offers a proprietary voice platform that leverages advanced natural language processing and machine learning technologies, ensuring high accuracy and a seamless user experience. By providing these innovative voice tools, Suki aims to alleviate the administrative burden on clinicians, ultimately transforming the healthcare technology landscape into a more assistive and integrated system.

Scope3

Series B in 2024
Scope3 operates a supply chain emissions data platform that provides accurate and comprehensive emissions data to assist companies in integrating sustainability into their business decisions. The company develops models that outline the core inputs and outputs for products and services within the supply chain, enabling organizations to design more sustainable systems. Additionally, Scope3 prepares monthly sustainability reports that offer updated emissions data, allowing businesses to swiftly adapt to external changes and recognize their efforts in reducing carbon footprints.

Vanilla

Series B in 2024
Vanilla is an innovative Estate Advisory Platform designed to enhance the estate planning experience for wealth management firms and their clients. By providing a comprehensive suite of tools, Vanilla enables advisors, planners, and estate attorneys to offer tailored advice, strengthen client relationships, and attract new business. The platform addresses inefficiencies in document preparation and enhances understanding of estate complexities, making it easier for clients to navigate estate-related challenges after a death. Ultimately, Vanilla aims to simplify and scale estate analysis, allowing estate professionals to deliver more value and support to their clients in managing estate tax considerations and planning effectively.

Element Biosciences

Series D in 2024
Element Biosciences, Inc. is a life science company based in San Diego, California, that specializes in developing innovative genetic analysis tools for research and diagnostics. Established in 2017, the company focuses on creating a modular and high-performing DNA sequencing platform designed to provide high-quality data and workflow flexibility. Their proprietary technology enhances the signal-to-noise ratio and incorporates advancements in surface chemistry, instrumentation, and biochemistry. This approach significantly reduces both operational and capital costs while ensuring superior sequencing data quality, thereby making next-generation sequencing technology more accessible to medical researchers and improving their research capabilities.

Tembo

Series A in 2024
Tembo is a developer of a scalable and secure platform that facilitates the building, deployment, and management of various data services and applications using Postgres databases. The company aims to make the extensive open-source Postgres ecosystem more accessible for common use cases, effectively productizing it. By doing so, Tembo reduces the reliance on specialized database management expertise, allowing clients to enhance the capabilities of their databases.

Bright Peak Therapeutics

Series C in 2024
Bright Peak Therapeutics is a biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. The company specializes in cytokine therapeutics that enable tissue and cell-specific targeting of cytokine payloads. This approach aims to enhance the efficacy of treatments, ultimately improving patient outcomes and quality of life. By leveraging innovative immuno-cytokines, Bright Peak seeks to provide more effective therapeutic options for complex medical conditions.

Archetype AI

Seed Round in 2024
Archetype AI is a group of designers and technologists they are pioneering revolutionary artificial intelligence and interaction technologies for the real world.

Accompany Health

Series A in 2024
Accompany Health is a health technology platform that delivers comprehensive in-home care to patients, particularly in underserved regions. The company focuses on providing primary care services, including chronic illness management and treatment of new symptoms. It aims to support low-income patients with complex health needs throughout their care journeys, offering both at-home and virtual services. By fostering long-term relationships with patients, Accompany Health ensures that individuals receive continuous support, with access to care available at all hours. This approach eliminates the need for waiting rooms and enhances the overall patient experience by emphasizing dignity and accessibility in healthcare.

SmithRx

Series C in 2024
SmithRx is a San Francisco-based company that specializes in designing and managing custom pharmacy benefit plans for employers. Founded in 2016, it operates on a modern technology platform that enhances flexibility, efficiency, and customer satisfaction in the pharmacy benefits space. The company aims to provide a cost-competitive pharmacy benefit management service through a pass-through model, a unified technology platform, and concierge-level support. By leveraging data analytics, SmithRx offers transparency and control over pharmacy benefits, enabling employers and their employees to better manage prescription costs. The team at SmithRx combines expertise from various healthcare and technology sectors, ensuring that clinical programs and alternative sourcing are effectively integrated into their service offerings. This approach not only focuses on reducing drug spending but also enhances the overall experience for members navigating their pharmacy benefits.

Zero Networks

Series B in 2023
Zero Networks Inc., founded in 2019 and based in Tel Aviv, Israel, specializes in cloud-based network security software. The company focuses on automating the development and enforcement of network access rules, allowing organizations to customize access for users and machines based on their communication patterns. Its technology eliminates the need for agents or manual policy configurations, providing a streamlined security solution. Additionally, Zero Networks includes a two-factor authentication mechanism that allows for secure connectivity even in unusual situations, ensuring that legitimate connections remain unaffected. By automating network access policies, Zero Networks aims to enhance security and prevent breaches, thereby safeguarding organizational operations.

RefleXion Medical

Venture Round in 2023
RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

MBrace Therapeutics

Series B in 2023
MBrace Therapeutics is a privately held biopharmaceutical company focused on enhancing the quality of life for cancer patients through the development of antibody-drug conjugates (ADCs). The company specializes in creating anti-tumor monoclonal human recombinant antibodies that target specific cancer cells. By utilizing advanced technology, MBrace Therapeutics aims to deliver potent toxic drugs directly into cancer cells, allowing for more precise treatment options. This innovative approach is designed to improve therapeutic outcomes and provide healthcare professionals with better tools to combat cancer.

Scope3

Series B in 2023
Scope3 operates a supply chain emissions data platform that provides accurate and comprehensive emissions data to assist companies in integrating sustainability into their business decisions. The company develops models that outline the core inputs and outputs for products and services within the supply chain, enabling organizations to design more sustainable systems. Additionally, Scope3 prepares monthly sustainability reports that offer updated emissions data, allowing businesses to swiftly adapt to external changes and recognize their efforts in reducing carbon footprints.

MOMENT

Series A in 2023
MOMENT is a private markets liquidity provider that operates a fixed-income infrastructure tailored for contemporary financial firms. The company aims to enhance the accessibility and fairness of fixed-income markets by delivering innovative solutions to global fintech companies, traditional brokerages, and registered investment advisors. MOMENT develops an institutional-grade platform that facilitates stable income generation through advanced technology. By offering application programming interfaces (APIs), it empowers various firms managing substantial assets to engage in fixed-income investing, thereby modernizing the financial market landscape.

Tisento Therapeutics

Series A in 2023
Tisento Therapeutics is a MA-based developer of novel medicines to treat diseases with significant unmet medical needs.

SQLite Cloud

Seed Round in 2023
SQLite Cloud is a cloud-based service that offers an easy-to-use and highly scalable platform for managing SQLite databases in the cloud. Our product provides a secure and reliable way to store, manage, and share SQLite databases without requiring any server setup or maintenance. With our service, customers can easily create new databases, import existing databases, and collaborate with others on their projects. Our product also offers various features such as automated backups, point-in-time recovery, and real-time replication, which ensures high availability and data durability. Our goal is to make database management as easy and hassle-free as possible for our customers.

Aledade

Series F in 2023
Aledade, Inc. is a health technology company that supports primary care physicians in establishing and managing accountable care organizations (ACOs) across the United States. Founded in 2014 and based in Bethesda, Maryland, Aledade partners with independent primary care providers to offer a comprehensive suite of services, including data analytics, guided workflows, regulatory expertise, and payer relationships. The company also provides 360° practice support, workflow optimization, and assistance with ACO governance and contracting. By leveraging its technology platform, Aledade enables physicians to access integrated data and insights that help improve patient care, reduce costs, and maintain the autonomy of independent practices. Its tailored solutions cater to a diverse range of healthcare providers, including small practices, large practices, community health centers, and multispecialty groups.

NeoPhotonics

Post in 2023
NeoPhotonics develops, manufactures, and sells a wide range of optical components designed for high-speed communication networks. The company offers both active and passive products that cater to various market segments, including fiber-to-the-home (FTTH), datacom, storage area networks, and metro and long-haul networks. Its portfolio includes transceivers compliant with industry standards, available in multiple configurations such as GBIC, SFF, and SFP, supporting data rates from 155 Mbps to 10 Gbps. Key products encompass integrated splitters, BiDi and TriPlexer transceivers for FTTH, as well as advanced optical modules and subsystems crucial for metro and long-haul dense wavelength division multiplexing (DWDM) networks. Additionally, NeoPhotonics manufactures various other components, including athermal array waveguide gratings, variable optical attenuators, and dynamic channel equalizers, enhancing the performance and efficiency of optical communication systems.

Airspeed

Seed Round in 2023
Airspeed is a team-building platform designed for modern companies to foster digital connections among employees. The platform offers a range of applications that provide engaging solutions for celebrating employee milestones, recognizing colleagues, and facilitating connections within hybrid or remote teams. By serving as a system of record for organizational culture, Airspeed helps businesses enhance employee engagement, retention, and productivity, ultimately contributing to a strong and collaborative company culture.

Tembo

Seed Round in 2023
Tembo is a developer of a scalable and secure platform that facilitates the building, deployment, and management of various data services and applications using Postgres databases. The company aims to make the extensive open-source Postgres ecosystem more accessible for common use cases, effectively productizing it. By doing so, Tembo reduces the reliance on specialized database management expertise, allowing clients to enhance the capabilities of their databases.

Nightfall

Series B in 2022
Nightfall is a cloud data protection platform that utilizes machine learning to identify and manage business-critical data across various applications. It integrates seamlessly with all SaaS, APIs, and data infrastructures, automatically classifying sensitive information to ensure comprehensive data protection. The platform addresses data exposure and hygiene issues without impacting end users by setting up automated workflows for quarantines, deletions, and alerts. Additionally, Nightfall offers a Developer Platform that provides flexible APIs and SDKs, allowing developers to incorporate its data classification and protection capabilities into their applications. This approach not only enhances security but also saves time for users, helping organizations maintain the safety of their business data.

Dgraph

Seed Round in 2022
Dgraph Labs, Inc. is a technology company based in San Francisco, California, that specializes in developing and operating a graph database. Founded in 2016, Dgraph offers a low-latency solution designed for efficient retrieval of structured data, catering to both small startups and large enterprises. Its flagship product, Slash Enterprise, is a fully-managed and serverless solution that supports terabytes of data and operates on dedicated, multi-zone clusters across major cloud platforms such as AWS, Azure, and GCP. The company's graph database is particularly suited for real-time user queries and addresses various use cases, including semantic search, pattern matching, and fraud detection, enabling clients to effectively manage, represent, and visualize large datasets.

Arch Data, Inc (fka Meltano)

Seed Round in 2022
Arch is an AI data analytics platform designed to deliver insights tailored to business needs, without requiring a full data team or complex toolchains. As an AI Data Analyst, Arch provides an all-in-one solution for extracting, analyzing, and visualizing data across your organization, ensuring you can make informed decisions quickly and confidently. Built to be intuitive and flexible, Arch is backed by human expertise for the highest accuracy, creating an invaluable resource for any size business looking to optimize performance, reduce costs, and drive growth. From real-time data insights to predictive analytics, Arch integrates seamlessly into your existing workflows, delivering insights wherever your teams operate—whether in Slack, email, or your CRM.

MOMENT

Seed Round in 2022
MOMENT is a private markets liquidity provider that operates a fixed-income infrastructure tailored for contemporary financial firms. The company aims to enhance the accessibility and fairness of fixed-income markets by delivering innovative solutions to global fintech companies, traditional brokerages, and registered investment advisors. MOMENT develops an institutional-grade platform that facilitates stable income generation through advanced technology. By offering application programming interfaces (APIs), it empowers various firms managing substantial assets to engage in fixed-income investing, thereby modernizing the financial market landscape.

The Public Health Company

Series A in 2022
The Public Health Company is focused on creating a global biosecurity platform that offers a Software as a Service (SaaS) solution for managing bio-risks within enterprises. Founded in 2020 and headquartered in Palo Alto, California, the company combines expert knowledge with advanced technology to provide a comprehensive approach to enterprise risk management. Its platform addresses various physical world threats, delivering actionable and predictive intelligence that enables dynamic risk management with exceptional speed and scale. The Public Health Company serves businesses, healthcare providers, and public health systems, positioning itself as a key player in enhancing public health and safety through innovative solutions.

Kelonia Therapeutics

Series A in 2022
Kelonia Therapeutics is developing a new wave of genetic medicines using its next-generation vivo gene delivery platform. The company's cutting-edge in vivo gene delivery technology is simple and elegant, relying on a few potent lentiviral vector-like particles to precisely and efficiently deliver genetic cargo to the desired target tissue, and only that tissue, every time. To deliver genetic cargo only to the desired tissue, the lentiviral vector gene delivery platform employs a simple and elegant solution based on decades of research, development, and technical experience. Kelonia's mission is to develop a new wave of accessible genetic medicines that will transform the lives of patients suffering from a broad range of conditions.

Vanilla

Series B in 2022
Vanilla is an innovative Estate Advisory Platform designed to enhance the estate planning experience for wealth management firms and their clients. By providing a comprehensive suite of tools, Vanilla enables advisors, planners, and estate attorneys to offer tailored advice, strengthen client relationships, and attract new business. The platform addresses inefficiencies in document preparation and enhances understanding of estate complexities, making it easier for clients to navigate estate-related challenges after a death. Ultimately, Vanilla aims to simplify and scale estate analysis, allowing estate professionals to deliver more value and support to their clients in managing estate tax considerations and planning effectively.

Quiq

Series C in 2022
Quiq, Inc. is a technology company that specializes in customer service messaging management software, enabling businesses to facilitate communication between consumers and brands through various digital messaging channels. Founded in 2015 and based in Bozeman, Montana, Quiq develops solutions that allow customer service agents and managers to connect with customers in a user-friendly manner, utilizing the same applications consumers use to communicate with friends. The company's flagship product, Quiq IQ, enables the creation and deployment of AI-driven bots for web chat and messaging. Additionally, Quiq offers a comprehensive AI Contact Center and advanced business process automation tools that support personalized and proactive customer experiences across multiple platforms, including SMS, WhatsApp, and Apple Messages for Business. With a focus on seamless integration and user experience, Quiq empowers brands to deliver efficient and cost-effective customer support while ensuring smooth transitions between AI and human agents. Its client roster includes notable companies such as Volvo and IHG Hotels & Resorts, reflecting its commitment to enhancing customer engagement through innovative technology.

Ocelot Bio

Series A in 2022
Ocelot Bio brings new treatment options to patients with severe liver disease. It researches and discovers medicines that help in the treatment of hepatorenal syndrome, a complication of severe liver disease.

Astronomer

Series C in 2022
Astronomer, Inc. is a company based in Cincinnati, Ohio, that specializes in developing a managed Apache Airflow platform for data engineering. Founded in 2014, Astronomer offers Astro, a modern data orchestration platform that helps data teams enhance the availability of trusted data. This platform empowers users to build, run, and monitor data pipelines-as-code, making it easier for data engineers, scientists, and analysts to manage their workflows. By providing a suite of products and services that facilitate the deployment, management, and scaling of data pipelines, Astronomer aims to streamline the process of data collection and preparation for business analytics. The company's solutions are designed to support isolated resource allocation, user access, and account management, positioning it as a key player in the data orchestration landscape.

SmithRx

Series B in 2022
SmithRx is a San Francisco-based company that specializes in designing and managing custom pharmacy benefit plans for employers. Founded in 2016, it operates on a modern technology platform that enhances flexibility, efficiency, and customer satisfaction in the pharmacy benefits space. The company aims to provide a cost-competitive pharmacy benefit management service through a pass-through model, a unified technology platform, and concierge-level support. By leveraging data analytics, SmithRx offers transparency and control over pharmacy benefits, enabling employers and their employees to better manage prescription costs. The team at SmithRx combines expertise from various healthcare and technology sectors, ensuring that clinical programs and alternative sourcing are effectively integrated into their service offerings. This approach not only focuses on reducing drug spending but also enhances the overall experience for members navigating their pharmacy benefits.

RefleXion Medical

Venture Round in 2022
RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

Astrix Security

Seed Round in 2022
Astrix Security specializes in protecting non-human identities such as API keys, service accounts, and access tokens, addressing a critical aspect of identity security for organizations. The company's cloud-based platform provides comprehensive visibility into these identities, enabling the automatic identification and mitigation of excessive or harmful access that can lead to supply chain threats and data breaches. By controlling the lifecycle of non-human identities, Astrix offers an agentless solution that enhances risk assessment and facilitates automated remediation. This allows organizations to safely harness the benefits of app-to-app integration and automation while minimizing the risk of service supply chain attacks.

Zero Networks

Series A in 2022
Zero Networks Inc., founded in 2019 and based in Tel Aviv, Israel, specializes in cloud-based network security software. The company focuses on automating the development and enforcement of network access rules, allowing organizations to customize access for users and machines based on their communication patterns. Its technology eliminates the need for agents or manual policy configurations, providing a streamlined security solution. Additionally, Zero Networks includes a two-factor authentication mechanism that allows for secure connectivity even in unusual situations, ensuring that legitimate connections remain unaffected. By automating network access policies, Zero Networks aims to enhance security and prevent breaches, thereby safeguarding organizational operations.

Decodable

Series A in 2022
Decodable is a data integration and engineering platform focused on serverless streaming data, founded in 2021 and based in San Francisco, California. The company provides software that enables applications and data engineers to construct complex data pipelines efficiently. Its platform facilitates quick connections to various messaging, storage, and database systems, allowing users to collect, process, and deliver data effectively to both offline and online systems.

3Box

Series A in 2022
3Box Inc. is a New York-based company founded in 2018 that provides innovative solutions for decentralized identity and open data management. Its primary offerings include 3box.io, a social profiles application designed for Ethereum users and communities, and 3box.js, an API that facilitates user onboarding and data management for web3 developers. Additionally, the company provides 3box-dapp, which enables users to create and manage their social profiles, sign in to decentralized applications (dApps), interact with other users, build a reputation, and securely store data. The 3Box platform prioritizes simplicity, security, and privacy, allowing applications that utilize its services to be more trustworthy and reduce data management liabilities.

Running Tide

Series B in 2022
Running Tide crafts adaptive aquaculture techniques to optimize nature while amplifying flavor and health. It applies the minds of scientists to produce exceptionally healthy low-carbon protein. Running Tide analyzes ocean data to determine how to better utilize two-thirds of the Earth’s surface in the climate fight.

Atom Computing

Series B in 2022
Atom Computing builds truly scalable quantum computers out of individual atoms. The company's quantum computers use quantum mechanical properties of atoms to process information and solve problems beyond the reach of traditional computers, including drug design, computational chemistry, and more. Atom Computing was founded in 2018 and based in Berkeley, California.

Mythic Therapeutics

Series B in 2021
Mythic Therapeutics is a biotechnology company dedicated to advancing cancer treatment through innovative antibody-drug conjugates (ADCs). The company specializes in a protein engineering approach that enhances the potency of ADCs while maintaining safety, allowing for more effective targeted therapies across various tumor types. By improving the uptake of these therapeutics in cancerous cells and minimizing payload release in healthy cells, Mythic Therapeutics aims to increase the efficacy of treatments without causing significant side effects or toxicity. This technology positions the company to make a meaningful impact in cancer care, enabling healthcare practitioners to better utilize ADCs for a wide array of patients.

Suki

Series C in 2021
Suki is a technology company focused on enhancing healthcare documentation through AI-driven voice solutions. Its flagship product, Suki Assistant, allows physicians to complete administrative tasks more efficiently, significantly reducing the time spent on documentation. The company also offers a proprietary voice platform that leverages advanced natural language processing and machine learning technologies, ensuring high accuracy and a seamless user experience. By providing these innovative voice tools, Suki aims to alleviate the administrative burden on clinicians, ultimately transforming the healthcare technology landscape into a more assistive and integrated system.

Altruist

Series C in 2021
Altruist is dedicated to enhancing the quality, affordability, and accessibility of independent financial advice. The company offers a digital investment platform that streamlines operations for financial advisors, enabling them to serve their clients more efficiently. By automating research and identifying problem areas, the platform allows advisors to provide better guidance, ultimately empowering clients to make informed financial decisions. This approach not only reduces costs for clients but also fosters greater financial confidence, positively impacting the experiences of tens of millions of individuals. Altruist supports a wide network of financial professionals, helping them deliver valuable services to their clients.

Skyryse

Series B in 2021
Skyryse, Inc. is an air mobility company founded in 2016 and headquartered in El Segundo, California. The company specializes in the development of helicopters and aircraft, targeting sectors such as emergency services, public transport, and urban planning. Skyryse has created a comprehensive hardware and software operating system known as FlightOS. This system provides a unified interface for pilots, allowing them to operate various types of aircraft, both rotorcraft and fixed-wing, using the same controls. By significantly reducing pilot fatigue and complexity, FlightOS enhances flight safety and improves emergency management. With just a few hours of training, any pilot can effectively fly any aircraft, whether from the cockpit or remotely, making aviation more accessible and efficient.

Stride Health

Series C in 2021
Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The company provides a range of affordable health coverage options, including dental plans, doctor visits, and prescription insurance. By simplifying the enrollment process, Stride Health enables users to quickly select their most cost-effective health plans while also offering assistance from personal advisors to help navigate any complexities. Founded in 2013 and based in San Francisco, California, Stride Health was previously known as Covered, Inc. The company's mission is to make health insurance more accessible and manageable for those who may not have traditional employment benefits.

Rebellion Defense

Venture Round in 2021
Rebellion Defense, Inc. is a technology company that creates software products utilizing artificial intelligence and machine learning to support national defense missions for the United States, United Kingdom, and allied nations. Established in 2019 and headquartered in Washington, D.C., with additional offices in Seattle and London, the company focuses on turning data into actionable insights to enhance decision-making in the security sector. Its advanced software solutions provide comprehensive analyses of the threat landscape, automate operational processes, and bolster cybersecurity for critical military assets. By integrating expertise from both the private technology sector and defense veterans, Rebellion Defense aims to equip warfighters with innovative capabilities to detect and counter threats effectively.

Vanilla

Series A in 2021
Vanilla is an innovative Estate Advisory Platform designed to enhance the estate planning experience for wealth management firms and their clients. By providing a comprehensive suite of tools, Vanilla enables advisors, planners, and estate attorneys to offer tailored advice, strengthen client relationships, and attract new business. The platform addresses inefficiencies in document preparation and enhances understanding of estate complexities, making it easier for clients to navigate estate-related challenges after a death. Ultimately, Vanilla aims to simplify and scale estate analysis, allowing estate professionals to deliver more value and support to their clients in managing estate tax considerations and planning effectively.

Atom Computing

Series A in 2021
Atom Computing builds truly scalable quantum computers out of individual atoms. The company's quantum computers use quantum mechanical properties of atoms to process information and solve problems beyond the reach of traditional computers, including drug design, computational chemistry, and more. Atom Computing was founded in 2018 and based in Berkeley, California.

Airspeed

Seed Round in 2021
Airspeed is a team-building platform designed for modern companies to foster digital connections among employees. The platform offers a range of applications that provide engaging solutions for celebrating employee milestones, recognizing colleagues, and facilitating connections within hybrid or remote teams. By serving as a system of record for organizational culture, Airspeed helps businesses enhance employee engagement, retention, and productivity, ultimately contributing to a strong and collaborative company culture.

Element Biosciences

Series C in 2021
Element Biosciences, Inc. is a life science company based in San Diego, California, that specializes in developing innovative genetic analysis tools for research and diagnostics. Established in 2017, the company focuses on creating a modular and high-performing DNA sequencing platform designed to provide high-quality data and workflow flexibility. Their proprietary technology enhances the signal-to-noise ratio and incorporates advancements in surface chemistry, instrumentation, and biochemistry. This approach significantly reduces both operational and capital costs while ensuring superior sequencing data quality, thereby making next-generation sequencing technology more accessible to medical researchers and improving their research capabilities.

Altruist

Series B in 2021
Altruist is dedicated to enhancing the quality, affordability, and accessibility of independent financial advice. The company offers a digital investment platform that streamlines operations for financial advisors, enabling them to serve their clients more efficiently. By automating research and identifying problem areas, the platform allows advisors to provide better guidance, ultimately empowering clients to make informed financial decisions. This approach not only reduces costs for clients but also fosters greater financial confidence, positively impacting the experiences of tens of millions of individuals. Altruist supports a wide network of financial professionals, helping them deliver valuable services to their clients.

Waybridge

Series B in 2021
Waybridge is a company that provides a logistics management platform aimed at addressing inefficiencies in the raw materials supply chain. Established in 2019 and headquartered in New York, Waybridge offers a suite of digital tools that enhance supply chain resilience, sustainability, collaboration, and effectiveness. The platform facilitates online negotiations to optimize purchasing, maximizes participant engagement, and supports trade analysis, while also providing real-time shipment tracking. By streamlining these processes, Waybridge enables clients to achieve substantial cost savings through improved supply chain optimization.

The Public Health Company

Seed Round in 2021
The Public Health Company is focused on creating a global biosecurity platform that offers a Software as a Service (SaaS) solution for managing bio-risks within enterprises. Founded in 2020 and headquartered in Palo Alto, California, the company combines expert knowledge with advanced technology to provide a comprehensive approach to enterprise risk management. Its platform addresses various physical world threats, delivering actionable and predictive intelligence that enables dynamic risk management with exceptional speed and scale. The Public Health Company serves businesses, healthcare providers, and public health systems, positioning itself as a key player in enhancing public health and safety through innovative solutions.

Astranis

Series C in 2021
Astranis is a satellite technology developer focused on providing high-speed internet access to underserved regions. The company aims to address the digital divide by launching satellites that can transmit data to specific terrestrial locations, facilitating internet connectivity for the estimated 4 billion people worldwide who currently lack access. By offering reliable internet services at significantly lower costs than traditional methods, Astranis enables governments and businesses to connect communities and expand internet access globally.

TAE

Venture Round in 2021
TAE Technologies, Inc. is a company focused on developing clean fusion energy through advanced particle accelerator and plasma physics. Founded in 1998 and headquartered in Foothill Ranch, California, with an additional office in Rancho Santa Margarita, TAE Technologies aims to create a new source of energy derived from natural processes that generates no harmful byproducts. With over two decades of research, the company is dedicated to commercializing safe and cost-effective fusion power solutions. TAE Technologies also contributes to advancements in power management, electric mobility, and life sciences, addressing the global energy demand while promoting sustainable and carbon-free energy alternatives.

Auditoria.AI

Series A in 2021
Auditoria.AI, Inc., founded in 2019 and based in Santa Clara, California, specializes in providing technology-driven financial solutions for enterprise accounting and auditing. The company leverages advanced artificial intelligence and machine learning to enhance compliance and streamline finance operations. Its flagship product utilizes natural language processing and predictive analytics to automate back-office processes, minimizing friction and repetition for finance teams. By focusing on automation, Auditoria.AI aims to deliver real-time insights that empower organizations to improve efficiency and decision-making in their financial operations.

Dapper Labs

Venture Round in 2021
Dapper Labs Inc., founded in 2018 and based in Vancouver, Canada, specializes in the development of blockchain-based gaming and collectible platforms. The company is well-known for its flagship product, NBA Top Shot, which utilizes blockchain technology to create non-fungible tokens (NFTs) that engage fans and enhance their connection to their favorite sports brands. Dapper Labs aims to empower consumers by providing them with opportunities to participate in digital ecosystems, allowing them to track ownership securely and become creators within these communities. Through its innovative approach, the company fosters engaging experiences and builds vibrant communities centered around digital collectibles and entertainment.

Dapper Labs

Series C in 2021
Dapper Labs Inc., founded in 2018 and based in Vancouver, Canada, specializes in the development of blockchain-based gaming and collectible platforms. The company is well-known for its flagship product, NBA Top Shot, which utilizes blockchain technology to create non-fungible tokens (NFTs) that engage fans and enhance their connection to their favorite sports brands. Dapper Labs aims to empower consumers by providing them with opportunities to participate in digital ecosystems, allowing them to track ownership securely and become creators within these communities. Through its innovative approach, the company fosters engaging experiences and builds vibrant communities centered around digital collectibles and entertainment.

Decodable

Seed Round in 2021
Decodable is a data integration and engineering platform focused on serverless streaming data, founded in 2021 and based in San Francisco, California. The company provides software that enables applications and data engineers to construct complex data pipelines efficiently. Its platform facilitates quick connections to various messaging, storage, and database systems, allowing users to collect, process, and deliver data effectively to both offline and online systems.

Cyteir Therapeutics

Series C in 2021
Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing innovative therapies that leverage the biology of DNA repair for cancer treatment and synthetic lethality in autoimmune diseases. The company utilizes its expertise in DNA damage response biology to create a pipeline of small molecule therapeutics aimed at selectively targeting vulnerabilities in cancer cells and inducing their self-destruction through DNA damage overload. Cyteir's lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, which is crucial for repairing double-strand DNA breaks. The company is dedicated to addressing a variety of hematological malignancies, solid tumors, and chronic autoimmune disorders through its integrated drug development platform. Founded in 2012, Cyteir is committed to advancing next-generation therapies that can improve patient outcomes in challenging disease states.

Sitka

Series A in 2021
Sitka, Inc. operates an online communication platform that connects patients with healthcare providers across various specialties, including endocrinology, neurology, orthopedics, pulmonology, and rheumatology. Founded in 2018 by experts in healthcare, technology, and policy, the company aims to transform specialty care in the United States by enhancing the capabilities of primary care providers and facilitating patient involvement in their care. The platform allows for personalized consultations, such as interpreting MRI results with board-certified doctors, thereby improving patients' understanding of their health conditions and enabling better decision-making. Headquartered in Carmel, California, Sitka is supported by a range of investors and is dedicated to fostering effective and trusted care delivery for all patients through its innovative solutions.

Altruist

Venture Round in 2021
Altruist is dedicated to enhancing the quality, affordability, and accessibility of independent financial advice. The company offers a digital investment platform that streamlines operations for financial advisors, enabling them to serve their clients more efficiently. By automating research and identifying problem areas, the platform allows advisors to provide better guidance, ultimately empowering clients to make informed financial decisions. This approach not only reduces costs for clients but also fosters greater financial confidence, positively impacting the experiences of tens of millions of individuals. Altruist supports a wide network of financial professionals, helping them deliver valuable services to their clients.

MBrace Therapeutics

Series A in 2021
MBrace Therapeutics is a privately held biopharmaceutical company focused on enhancing the quality of life for cancer patients through the development of antibody-drug conjugates (ADCs). The company specializes in creating anti-tumor monoclonal human recombinant antibodies that target specific cancer cells. By utilizing advanced technology, MBrace Therapeutics aims to deliver potent toxic drugs directly into cancer cells, allowing for more precise treatment options. This innovative approach is designed to improve therapeutic outcomes and provide healthcare professionals with better tools to combat cancer.

RayzeBio

Series B in 2020
RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. It specializes in developing tumor-targeted small molecule medicines that utilize the therapeutic potential of radioisotopes, particularly Actinium-225, an alpha-emitting radioisotope aimed at treating solid tumors. RayzeBio is focused on enhancing cancer treatment outcomes by creating a robust pipeline of radiopharmaceutical candidates targeting validated oncology drug targets. The company's portfolio includes a range of drug candidates at various stages of development, from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.

Luma

Seed Round in 2020
Luma, Inc. designs and develops a platform for managing events, focusing on both virtual and in-person experiences. Founded in 2020 and based in San Francisco, California, the company offers a range of features, including ticket sales, attendance tracking, and analytics. Luma enables users to host virtual classes, record live shows, and connect with their communities through integrated tools. The platform supports event promotion and management, allowing users to send invitations and accept tips and memberships. Overall, Luma aims to enhance the event-hosting experience by providing a comprehensive suite of services for organizers and attendees alike.

Pharvaris

Series C in 2020
Pharvaris is a clinical-stage company dedicated to the discovery and development of therapies for rare diseases, particularly focusing on hereditary angioedema (HAE) and other conditions mediated by bradykinin. The company is advancing an oral bradykinin B2 receptor antagonist, with its lead candidate, PHA121, currently undergoing Phase 1 clinical trials. Pharvaris aims to provide new treatment options that offer alternatives to injected therapies for all sub-types of HAE. The company was co-founded by key individuals involved in the development of icatibant, a previously established treatment for HAE, ensuring a strong foundation in this therapeutic area.

Mable

Series A in 2020
Mable is an online wholesale platform designed for retailers and distributors to discover and purchase products. Founded in 2019 and headquartered in Boston, Massachusetts, Mable offers a diverse range of brands, including Black Dinah Chocolatiers, Brave Coffee & Tea, Coastal Craft Kombucha, Crown Maple, Eddie's Bakery, Loco Coffee, Real Food Bar, and STOKES Firestarters. The platform serves as a mobile and web-based B2B e-commerce solution specifically tailored for grocers, facilitating the buying process in the wholesale market.

Federation Bio

Series A in 2020
Federation Bio Inc. is focused on developing microbial therapeutics aimed at curing various diseases through the human microbiome. The company utilizes platforms that harness naturally occurring or engineered bacteria, along with a supportive community of bacteria, to promote engraftment and achieve lasting therapeutic responses. Its research encompasses a broad spectrum of conditions, including secondary hyperoxaluria, metabolic disorders, immune diseases, cholestatic diseases, and cancer. Founded in 2018 and headquartered in South San Francisco, California, Federation Bio was previously known as Comet Medicine Inc. before rebranding in April 2019.

Olema Oncology

Series C in 2020
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for estrogen receptor (ER) positive breast cancer. The company specializes in the discovery and commercialization of targeted treatments aimed at improving outcomes for women with cancer. Olema utilizes its extensive knowledge of endocrine-driven cancers and the molecular mechanisms of the ER to create drug candidates that are designed to outperform existing therapies. Currently, the company's product pipeline includes OP-1250 and OP-3136, both of which have completed discovery and preclinical studies. Olema's mission is to transform the standard of care for both pre- and post-menopausal women by providing more effective and convenient treatment options.

Mythic Therapeutics

Venture Round in 2020
Mythic Therapeutics is a biotechnology company dedicated to advancing cancer treatment through innovative antibody-drug conjugates (ADCs). The company specializes in a protein engineering approach that enhances the potency of ADCs while maintaining safety, allowing for more effective targeted therapies across various tumor types. By improving the uptake of these therapeutics in cancerous cells and minimizing payload release in healthy cells, Mythic Therapeutics aims to increase the efficacy of treatments without causing significant side effects or toxicity. This technology positions the company to make a meaningful impact in cancer care, enabling healthcare practitioners to better utilize ADCs for a wide array of patients.

Olema Oncology

Series B in 2020
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for estrogen receptor (ER) positive breast cancer. The company specializes in the discovery and commercialization of targeted treatments aimed at improving outcomes for women with cancer. Olema utilizes its extensive knowledge of endocrine-driven cancers and the molecular mechanisms of the ER to create drug candidates that are designed to outperform existing therapies. Currently, the company's product pipeline includes OP-1250 and OP-3136, both of which have completed discovery and preclinical studies. Olema's mission is to transform the standard of care for both pre- and post-menopausal women by providing more effective and convenient treatment options.

VelosBio

Series B in 2020
VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various forms of cancer, including hematological cancers and solid tumors. The company's primary area of research centers on targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein found in numerous tumors but absent in normal tissues, which makes it a promising target for cancer therapy. VelosBio's lead product, VLS-101, is a ROR1-directed ADC that has shown positive preclinical results and aims to provide new treatment options for patients. Founded in 2017, VelosBio operates under the umbrella of Merck & Co., Inc. as of December 2020, focusing on developing targeted therapies that can be administered alone or in combination with other treatments across a wide range of cancer types.

CVRx

Venture Round in 2020
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.

Astronomer

Series A in 2020
Astronomer, Inc. is a company based in Cincinnati, Ohio, that specializes in developing a managed Apache Airflow platform for data engineering. Founded in 2014, Astronomer offers Astro, a modern data orchestration platform that helps data teams enhance the availability of trusted data. This platform empowers users to build, run, and monitor data pipelines-as-code, making it easier for data engineers, scientists, and analysts to manage their workflows. By providing a suite of products and services that facilitate the deployment, management, and scaling of data pipelines, Astronomer aims to streamline the process of data collection and preparation for business analytics. The company's solutions are designed to support isolated resource allocation, user access, and account management, positioning it as a key player in the data orchestration landscape.

Iris Medicine

Seed Round in 2020
Iris Medicine is a biotechnology company founded in 2019 and based in Palo Alto, California. It specializes in developing novel therapeutics aimed at the pharmaceutical and healthcare sectors. The company's focus is on creating RNA medicines that target serious diseases, particularly those that have limited or no existing treatment options. By advancing these innovative therapies, Iris Medicine seeks to assist medical professionals in effectively managing and treating neurological diseases.

RefleXion Medical

Series D in 2020
RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

ABL Space Systems

Venture Round in 2020
ABL Space Systems specializes in designing and manufacturing rockets for the launch of small satellites. Incorporated in 2017 and based in El Segundo, California, the company focuses on developing low-cost and reliable launch vehicles, with its primary product being the RS1 rocket. This vehicle is capable of carrying payloads of up to 1,350 kilograms to Low Earth Orbit (LEO) and supports various configurations, including multi-manifest and dedicated deployments. In addition to the RS1, ABL also creates the GS0 ground system, which facilitates rapid deployment and integration of launch operations at multiple sites. The company operates from a 30,000 square foot facility dedicated to research, development, and production, and is privately owned, supported by a group of private equity investors.

Lyra Health

Series C in 2020
Lyra Health, Inc. is a digital health company based in Burlingame, California, founded in 2015. It operates a platform that connects employers with a curated network of mental health care providers, including therapists and coaches. Lyra's innovative technology matches employees to the appropriate mental health resources based on their individual needs and preferences, enhancing access to high-quality care. The platform employs clinical measures to assess symptom improvement for common mental health issues, leading to significantly better outcomes compared to traditional plans. By offering live video therapy, coaching, and digital self-care tools, Lyra facilitates a comprehensive treatment journey for its members, resulting in increased engagement and support throughout the mental health process.

Keros Therapeutics

Series C in 2020
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, specifically anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is advancing KER-047, a small molecule therapy aimed at treating anemia caused by elevated hepcidin levels, as well as fibrodysplasia ossificans progressiva. Another candidate, KER-012, is being developed for conditions related to bone loss, such as osteoporosis and osteogenesis imperfecta, and for pulmonary arterial hypertension. Founded in 2015, Keros Therapeutics is headquartered in Lexington, Massachusetts.

Suki

Series B in 2020
Suki is a technology company focused on enhancing healthcare documentation through AI-driven voice solutions. Its flagship product, Suki Assistant, allows physicians to complete administrative tasks more efficiently, significantly reducing the time spent on documentation. The company also offers a proprietary voice platform that leverages advanced natural language processing and machine learning technologies, ensuring high accuracy and a seamless user experience. By providing these innovative voice tools, Suki aims to alleviate the administrative burden on clinicians, ultimately transforming the healthcare technology landscape into a more assistive and integrated system.

Astranis

Series B in 2020
Astranis is a satellite technology developer focused on providing high-speed internet access to underserved regions. The company aims to address the digital divide by launching satellites that can transmit data to specific terrestrial locations, facilitating internet connectivity for the estimated 4 billion people worldwide who currently lack access. By offering reliable internet services at significantly lower costs than traditional methods, Astranis enables governments and businesses to connect communities and expand internet access globally.

Virta Health

Series C in 2020
Virta Health Corp. is an online specialty medical clinic dedicated to reversing type 2 diabetes without the use of medications or surgery. Founded in 2014 and based in San Francisco, California, the company utilizes a combination of nutritional biochemistry, clinical expertise, data science, and digital solutions to deliver its innovative treatment. Through its continuous remote care platform, Virta provides extensive medical and behavioral support, which has shown significant results in clinical trials; 60% of enrolled patients achieved diabetes reversal after one year, while 94% of insulin users reduced or eliminated their insulin intake. The benefits of Virta's approach extend beyond diabetes, leading to improvements in blood pressure, inflammation, liver function, and body mass index (BMI), thereby transforming the lives of individuals affected by type 2 diabetes.

Element Biosciences

Series B in 2020
Element Biosciences, Inc. is a life science company based in San Diego, California, that specializes in developing innovative genetic analysis tools for research and diagnostics. Established in 2017, the company focuses on creating a modular and high-performing DNA sequencing platform designed to provide high-quality data and workflow flexibility. Their proprietary technology enhances the signal-to-noise ratio and incorporates advancements in surface chemistry, instrumentation, and biochemistry. This approach significantly reduces both operational and capital costs while ensuring superior sequencing data quality, thereby making next-generation sequencing technology more accessible to medical researchers and improving their research capabilities.

Inscripta

Series D in 2019
Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, the company is focused on developing advanced CRISPR enzymes, specifically its proprietary MADzymes, to facilitate precision gene editing. Inscripta has created the first benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that enable fully automated workflows for massively parallel editing of single cells. This innovative platform aims to empower scientists by overcoming existing technical and licensing challenges in gene editing research. By providing tools that allow for the generation of extensive libraries of designer proteins and genome variants, Inscripta supports researchers in designing, engineering, and evaluating genetic modifications with unprecedented ease and efficiency.

Nightfall

Series A in 2019
Nightfall is a cloud data protection platform that utilizes machine learning to identify and manage business-critical data across various applications. It integrates seamlessly with all SaaS, APIs, and data infrastructures, automatically classifying sensitive information to ensure comprehensive data protection. The platform addresses data exposure and hygiene issues without impacting end users by setting up automated workflows for quarantines, deletions, and alerts. Additionally, Nightfall offers a Developer Platform that provides flexible APIs and SDKs, allowing developers to incorporate its data classification and protection capabilities into their applications. This approach not only enhances security but also saves time for users, helping organizations maintain the safety of their business data.

Cyteir Therapeutics

Series B in 2019
Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing innovative therapies that leverage the biology of DNA repair for cancer treatment and synthetic lethality in autoimmune diseases. The company utilizes its expertise in DNA damage response biology to create a pipeline of small molecule therapeutics aimed at selectively targeting vulnerabilities in cancer cells and inducing their self-destruction through DNA damage overload. Cyteir's lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, which is crucial for repairing double-strand DNA breaks. The company is dedicated to addressing a variety of hematological malignancies, solid tumors, and chronic autoimmune disorders through its integrated drug development platform. Founded in 2012, Cyteir is committed to advancing next-generation therapies that can improve patient outcomes in challenging disease states.

Mable

Seed Round in 2019
Mable is an online wholesale platform designed for retailers and distributors to discover and purchase products. Founded in 2019 and headquartered in Boston, Massachusetts, Mable offers a diverse range of brands, including Black Dinah Chocolatiers, Brave Coffee & Tea, Coastal Craft Kombucha, Crown Maple, Eddie's Bakery, Loco Coffee, Real Food Bar, and STOKES Firestarters. The platform serves as a mobile and web-based B2B e-commerce solution specifically tailored for grocers, facilitating the buying process in the wholesale market.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.